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Glycolipids are complex molecules consisting of a ceramide lipid moiety linked to a glycan 
chain of variable length and structure. Among these are found the gangliosides, which 
are sialylated glycolipids ubiquitously distributed on the outer layer of vertebrate plasma 
membranes. Changes in the expression of certain species of gangliosides have been 
described to occur during cell proliferation, differentiation, and ontogenesis. However, 
the aberrant and elevated expression of gangliosides has been also observed in different 
types of cancer cells, thereby promoting tumor survival. Moreover, gangliosides are 
actively released from the membrane of tumor cells, having a strong impact on impairing 
anti-tumor immunity. Beyond the undesirable effects of gangliosides in cancer cells, a 
substantial number of cancer immunotherapies have been developed in recent years 
that have used gangliosides as the main target. This has resulted in successful immune 
cell- or antibody-responses against glycolipids, with promising results having been 
obtained in clinical trials. In this review, we provide a general overview on the metabolism 
of glycolipids, both in normal and tumor cells, as well as examining glycolipid-mediated 
immune modulation and the main successes achieved in immunotherapies using gangli-
osides as molecular targets.
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inTRODUCTiOn
Differentially expressed tumor-associated carbohydrates represent a general phenomenon observed 
in many types of cancer cells. Carbohydrates covalently attached to glycolipids are not the exception. 
Neosynthesized glycolipids observed in oncogenic processes show antigen specificity and, therefore, 
they are attractive candidates for the design of cancer vaccines. The poor immunogenicity, low-affinity 
immunoglobulin responses, and immunotolerance associated with glycolipids have been overcome 
with the advent of new technologies and combinatorial immunotherapies. Nevertheless, these 
remarkable advances are being counteracted for striking effects on anti-tumor immunity exerted by 
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particular molecular species of tumor-secreted glycolipids and, 
hence, strategies involving the use of glycolipid synthesis inhibi-
tors are being considered.
GLYCOLiPiD MeTABOLiSM AnD 
FUnCTiOnS
Glycolipids are molecules containing one or more carbohydrate 
residues linked to a hydrophobic lipid moiety via a β-glycosidic 
linkage. Those containing either a sphingoid or a ceramide as the 
hydrophobic lipid moiety are referred to as glycosphingolipids 
(GSLs). A particular subclass of glycolipids is the gangliosides, 
which are sialylated GSLs mainly expressed in the outer layer of 
the plasma membrane of essentially all vertebrate cells. The bio-
synthesis of gangliosides starts with the synthesis of ceramide at 
the cytoplasmic leaflet of the endoplasmic reticulum membrane, 
where the pyridoxal 5′-phosphate-dependent serine palmitoyl-
transferase catalyzes the condensation of palmitoyl- or stearoyl-
Coenzyme A with l-serine to give 3-ketosphinganine, which is 
reduced to d-erythro-sphinganine by 3-ketosphinganine reduc-
tase in a NADPH-dependent reaction. d-erythro-sphinganine 
is further acylated to generate different dihydroceramides by a 
family of ceramide synthases. Next, dihydroceramide is unsatu-
rated at the 4,5 position by DES1 desaturase to make ceramide. 
The de novo synthesized ceramide is then transported from the 
endoplasmic reticulum to the trans Golgi, at least in part in a 
protein-dependent manner by the transport protein CERamide 
Transport (CERT), where it is catalytically converted to glucosyl-
ceramide (GlcCer) by the action of UDP-Glc:ceramide glucosyl-
transferase. Most GlcCer may subsequently be transported by the 
four-phosphate adaptor protein 2 (a glycolipid-transport protein 
carrying a PI4P-binding domain) either to the endoplasmic 
reticulum or to distal Golgi compartments, where it translocates 
to the lumen. β4GalT-VI converts GlcCer to lactosylceramide 
(LacCer) and further carbohydrate residues, including negatively 
charged sialic acid, are transferred in a stepwise manner to the 
growing glycan chains (Figure 1A). Sialylated derivatives from 
LacCer are produced by the action of ST3Gal-V, ST8Sia-I, and 
ST8Sia-I/ST8Sia-V, which specifically catalyze the formation of 
the gangliosides GM3, GD3, and GT3, respectively. LacCer, GM3, 
GD3, and GT3 serve as precursors for more complex gangliosides 
of the 0-, a-, b-, or c-series by sequential glycosylations catalyzed 
by β4GalNAcT-I, β3GalT-IV, ST3Gal-II, and ST8Sia-V. After 
synthesis at the Golgi complex, gangliosides are mainly delivered 
by vesicular transport to the plasma membrane, where they can 
undergo endocytosis. In addition to the bulk ganglioside synthe-
sis at the Golgi complex level, ganglioside formation by plasma 
membrane-associated glycosyltransferases has been recently also 
reported (1–4). See Ref. (5–9) for an extensive review on ganglio-
side biosynthesis and molecular transport pathways.
The catabolism of gangliosides takes place mainly at the lys-
osomes, although degradation of gangliosides can also occur at 
the cell surface by the action of the sialidase Neu3, β-galactosidase, 
and β-glucosidase (10–14). At the lysosomal level, gangliosides 
are sequentially degraded by the action of glycosidases that 
sequentially cleave off the monosaccharide units from the 
non-reducing end of the ganglioside glycan chains. Adequate 
lysosomal ganglioside catabolism requires the presence of an 
appropriate pH, suitable glycosidases, and lipid-transfer proteins 
for the degradation of simple gangliosides, which extracts the 
membrane-bound glycolipids and presents them to the soluble 
acid hydrolase [see Ref. (15–17) for an extensive review on path-
ways of ganglioside catabolism].
Ganglioside expression changes with cell growth, differentia-
tion, viral transformation, oncogenesis, and ontogenesis (18–21). 
Gangliosides, originally identified as structural components of 
biomembranes, were later acknowledged as key lipids implicated 
in a range of cellular processes. Thus, gangliosides are involved in 
many physiological processes, including growth, differentiation, 
migration, and apoptosis through modulating both cell signaling 
processes and cell-to-cell and cell-to-matrix interactions (22–28). 
Moreover, gangliosides have been associated with a wide range 
of pathological processes, being receptors for viruses, toxins, and 
autoantibodies associated with clinically identifiable acute and 
chronic neuropathy syndromes. In addition, inherited defects in 
the biosynthesis or degradation of gangliosides have also been 
described, which causes a group of diseases mainly associated 
with severe neurodegenerative disorders (29–34).
Although the plasma membrane is the major cellular reservoir 
of gangliosides, it is not the final destination for these molecules. 
Thus, in addition to cell internalization, sorting to lysosomes or 
plasma membrane recycling, gangliosides can be actively shed 
from the membrane of one cell and taken up by other cells by 
insertion of their lipid anchors into the cell membrane. Although 
the shedding and uptake of gangliosides are a physiological pro-
cess observed in many types of cells, increased levels have been 
detected in various tumors, such as melanomas, renal carcinoma, 
astrocytomas, and glioblastomas (35–39). Many reports have 
described that shedding of gangliosides helps to suppress the 
immune response, probably by modifying membrane composi-
tion of immune cells and, hence, inhibiting their function and 
allowing tumor escape. This topic is further reviewed below.
GLYCOLiPiD-MeDiATeD iMMUne 
MODULATiOn
Tumors have a complex interrelation with the immune system. 
The immunoediting paradigm (40) describes how pressure 
exerted by immune cells recognizing and eliminating tumor 
cells results in the selection for poorly recognized malignant 
cells. Tumors can further disrupt this apparent equilibrium by 
inducing an immunosuppressive environment that allows tumor 
cells escape (41). Gangliosides shed from tumors and reaching 
immune cells have potential to contribute mechanisms suppress-
ing the immune system. Innate immunity cell populations, such 
as monocytes, macrophages, and dendritic cells (DC), kill tumor 
cells directly, release inflammatory mediators to recruit and 
differentiate adaptive immune cells, and present tumor antigens 
to T cells (42–44). Natural killer (NK) cells kill tumors directly 
depending on the balance between inhibitory and activating 
signals from invariant receptors (45). Natural killer T (NKT) 
cells can target lipid and glycolipid antigens in the context of 
FiGURe 1 | Synthesis and immunomodulatory effect of gangliosides.  
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(MHC-I resembling) CD1 molecules and mediate anti-tumor 
effects (46). Among the adaptive immunity cell populations, we 
find B cells (producing anti-tumor antibodies targeting cancer 
cells for killing by effector cells, and presenting antigen to T cells), 
as well as CD4+ T cells (helping with antibody production and 
cell-mediated immune responses) and CD8+ T cells [effector 
cells for tumor killing (47)]. The immunomodulatory effects by 
gangliosides take place to the level of both, the innate and the 
adaptive immunity (Figure 1B).
Mechanisms Suppressing innate immunity
Human brain gangliosides impede up-regulation of the costimu-
latory molecule CD80 (without affecting expression of I-CAM-1, 
LFA-3, HLA-DR, and CD86) on monocytes (48). Similarly, 
exposing monocytes to GD1a also inhibits CD80 up-regulation, 
decreases CD40 levels, and reduces LPS-stimulated interleukin 
(IL)-12 and TNF-α (49) by impeding NF-κB mobilization (50). In 
addition, pre-incubation of monocytes with certain gangliosides 
can impair Fc receptor expression (by GM2 and GM3), IL-1 
production (by GM1 and GD3) (51), and TLR signaling (52). 
Moreover, GM3 reduces the monocyte adhesion to endothelial 
cells (53). Importantly, tumor-derived gangliosides can increase 
number and function of myeloid-derived suppressor cells to favor 
immune escape (54).
Gangliosides, such as GM2 (55), GD1a (56), GM3, and GD3 
(57), can affect in vitro development and function of monocyte-
derived DC. Expression of MHC class II, costimulatory mol-
ecules, and CD116 (GM-CSF receptor) on DC is reduced by 
GM2. Endocytic, chemotactic, and T cell proliferation-inducing 
activities are also targeted. Meanwhile, GD1a mediates a poor 
DC response to activating conditions by reducing costimulatory 
molecules, IL-12, TNF-α, and IL-6 production, and increasing 
IL-10 release (49, 56), presumably through NF-κB activation dis-
ruption. This impaired response of activated DC is also observed 
with GM3 and GD3 (57), which also induce caspase 3-mediated 
apoptosis (57–59). NK cell cytotoxicity against tumor cells is 
reduced by tumor gangliosides binding to inhibitory receptors 
such as Siglec-7 and -9 (60–62). Finally, gangliosides can also 
interfere with NKT cells activation, such as GD3 in ovarian can-
cer (63) and GM2 in lymphoma (64), often acting as inhibitory 
ligands for the CD1d-mediated NKT cell response.
Mechanisms Suppressing Adaptive 
immunity
GM2 and GM3 gangliosides added in  vitro to B cells inhibit 
spontaneous production of IgG subclasses and IgM, with no 
effect on IgA subclasses (65). At least for GM2, the mechanism 
involves reduction of endogenous IL-10 and TNF-α produc-
tion (66), while the presence of TNF-α can counteract these 
inhibitions. In addition, certain complex gangliosides can 
affect IL-6 and IL-10 production on CD4+ T cells (GD1b) and 
monocytes (GT1b) (67, 68), also leading to further reduced 
IgG, IgM, and IgA antibody production in co-cultures with B 
cells. Remarkably, GQ1b and GD1a can abrogate the effects of 
GD1b and GT1b to enhance Ig production by human peripheral 
blood mononuclear cells (69, 70). It is noteworthy to mention 
that no effects have been described for gangliosides on antigen 
presentation by B cells.
Regarding T cells, gangliosides can have effects at both, central 
(71) and peripheral (72) T cell compartments. The induction of 
cytolytic anti-tumor immunity relies on type-1 T cell responses 
[conducted by interferon (IFN)-γ- and IL-2-producing T cells 
(73)], as opposed to type-2 T cell responses (defined by T cells 
producing IL-4, IL-6, and IL-10) leading to cytolytic activity sup-
pression (74). Indeed, cancer patients produce increased type-2 
cytokines (75). Several genes participate in T cell development, 
maturation, and proliferation, under transcriptional control of 
Rel/NF-κB (76). Renal cell carcinoma (RCC)-derived gangliosides 
reduce IL-2 and IFN-γ expression (77) and increase apoptosis in 
T cells through NF-κB inhibition by reducing RelA(p65), p50, 
and antiapoptotic protein Bcl-xL (78). Tumor- or brain-derived 
gangliosides present during in vitro activation-induced settings 
(e.g., with anti-CD3 antibody) also associate with type-2 response 
shifts in CD4+ and CD8+ T cell populations by decreasing IFN-γ 
and often elevating IL-4 (79–81), along with increased apoptosis. 
Interestingly, in vivo findings show more apoptotic T cells in RCC 
patients having GM2 in their membranes but with negligible 
mRNA expression levels for GM2 synthase (82). This ectopic 
presence of GM2 could derive from the tumor and participate 
in apoptosis mediated by diverse mechanisms (82–86). Antigen-
specific T cell activation is also interfered by the presence of 
gangliosides. These effects are mediated by IL-2 transcription 
blockade and phosphorylation inhibition of retinoblastoma 
protein in activated human T cells (81). Moreover, ganglioside 
mixtures can inhibit proliferation of IL-2-dependent T cell lines 
by a competitive inhibition for IL-2 binding to IL-2R, mediated 
by direct binding of gangliosides to a lectin-like site on IL-2 (87).
In  vivo mice models indicate that cytotoxic CD8+ T cell 
populations are also affected by gangliosides exposure, in terms 
of expansion and tumor-specific responses to secondary chal-
lenges with tumor cells (88). In addition, gangliosides prevent 
TCR-induced lytic granule polarization, immunological synapse 
(A) Pathway for ganglioside biosynthesis representing the stepwise addition of monosaccharides to ceramide, and the resulting structures. β4GalT-VI, UDP-
Gal:glucosylceramide galactosyltransferase; ST3Gal-V, CMP-NeuAc:lactosylceramide sialyltransferase; ST8Sia-I, CMP-NeuAc:GM3 sialyltransferase, and 
CMP-NeuAc:GD3 sialyltransferase; β4GalNAcT-I, UDP-GalNAc:lactosylceramide/GM3/GD3/GT3 N-acetylgalactosaminyl transferase; β3GalT-IV, UDP-Gal:GA2/
GM2/GD2/GT2 galactosyltransferase; ST3Gal-II, CMP-NeuAc:GA1/GM1/GD1b/GT1c sialyltransferase; ST8Sia-V, CMP-NeuAc:GM1b/GD1a/GT1b/GQ1c 
sialyltransferase, and CMP-NeuAc:GD3 sialyltransferase. Cer, ceramide; Glc, glucose; Gal, galactose; GalNAc, N-acetylgalactosamine; Neu5Ac, N-acetylneuraminic 
acid (sialic acid). (B) Mechanisms for glycolipid-mediated immune modulation. Tumors shed gangliosides to extracellular milieu, where they are in dynamic 
equilibrium between monomeric, multimeric, and larger, hetero-complexed forms. From these various states, they have the potential to transfer to different immune 
cells, modify their membrane composition, and induce modifications that modulate innate and adaptive immunity. The summarized changes can thus favor tumor 
escape.
FiGURe 1 | Continued
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accumulation, and exocytosis, without interfering on lytic mol-
ecule expression or target cell recognition (89).
Despite all these detrimental effects, the bright side of gan-
glioside dysregulation in tumors is the opportunity to aim them 
as molecular targets. Next section presents current promising 
immunotherapy strategies based on this principle.
iMMUnOTHeRAPieS USinG 
GAnGLiOSiDeS AS MOLeCULAR 
TARGeTS
Among the reported changes on lipid composition of tumor cell 
membranes, the remarkable modifications on the sialic acid-
containing glycolipids during neoplastic transformations have 
received special attention. This spectrum also includes molecules 
such as lacto- and neolacto-series glycolipids and globosides 
(GSLs containing acetylated amino sugars and simple hexoses). 
Tumors, such as melanoma, small-cell lung cancer (SCLC), sar-
coma, and neuroblastoma, express gangliosides GD3, GM2, and 
GD2 in higher levels than corresponding normal tissue (90–94). 
Moreover, ganglioside derivatives, including N-glycolyl GM3 
(NeuGcGM3) and fucosyl-GM1, are also increased (94–97). 
Therefore, a substantial number of cancer immunotherapies have 
been using sialylated glycolipids as major targets. However, no 
glycolipid-containing cancer vaccines have produced substantial 
clinical improvements. Nevertheless, several reviews have recently 
covered in depth and from different perspectives a renewed inter-
est in therapeutic applications of glycoconjugates. Due to the 
stronger support based on the recent development of new tools 
and techniques, along with advances in the glycobiology field 
and potential combination with other therapeutic approaches, 
the authors share a common denominator: the re-emergence of 
gangliosides as promising targets for developing cancer therapeu-
tic agents (18, 41, 98–102). An example is GD3, highly expressed 
in tumor cells (>80% of melanomas) (90). Investigations focus-
ing on this ganglioside as principal target were made in passive 
(103) and active (104) immunotherapy of melanoma cancer, with 
modest results (105). However, a recent strategy is evaluating a 
GD3-specific chimeric antigen receptor (CAR) to redirect T cell 
specificity to GD3 expressed on tumor cells surface (90) (Table 1). 
Recently, GD3 has been proposed as a suitable immunotherapy 
target for tumors developed in lymphangioleiomyomatosis (106). 
In this sense, the mouse monoclonal R24 antibody (IgG3) against 
ganglioside GD3 is a validated tumor targeting agent (107). Our 
laboratory demonstrated that the R24 antibody, after binding 
to GD3 at the cell surface, is rapidly internalized and accumu-
lated in endosomal structures (108). We took advantage of this 
internalization feature for selectively delivering the toxin saporin 
(a ribosome-inactivating protein) to GD3-expressing human 
(SK-Mel-28) and mouse (B16) melanoma cells (109). This repre-
sented the first proof-of-concept of an original strategy in which 
a glycolipid emerges as a novel and attractive class of cell surface 
molecule for targeted drug delivery. Recently, this experimental 
strategy was also used for selective ablation of cell lines expressing 
9-O-acetyl GD3 (110). Thus, ganglioside GD3 re-emerges as an 
attractive cell surface molecule for targeted delivery of cytotoxic 
agents such as saporin or, eventually, other drugs such as pacli-
taxel (Taxol) and doxorubicin (111, 112).
One of the strategies to generate an effective immune 
response against tumor-associated carbohydrate antigens 
(TACAs) involves the use of anti-idiotype antibodies as antigen 
surrogates. Although several investigations support the role of 
GM3 in suppression of cancer development and progression 
(99), overexpression of NeuGcGM3 has received special atten-
tion because it is minimally expressed on most normal human 
tissues. In the 1990s, it was described an anti-idiotypic murine 
monoclonal antibody (1E10) that reacts with a monoclonal IgM 
antibody (P3) binding to N-glycolyl-containing gangliosides. 
1E10, commercially named racotumomab, mimics NeuGcGM3 
ganglioside to induce a strong anti-metastatic effect in tumor-
bearing mice (126). Racotumomab is being evaluated for a wide 
range of NeuGcGM3-expressing tumors such as melanoma, 
breast cancer, non-SCLC, and several pediatric tumors of neu-
roectodermal origin (113, 127–133). A Phase II/III multicenter 
double-blind clinical trial evaluated racotumomab vaccine effects 
in the overall survival in advanced non-SCLC patients (134). This 
study showed a significant clinical benefit for patients treated with 
the anti-idiotype vaccine. On the basis of these promising results, 
racotumomab was launched in 2013 in Cuba and Argentina as an 
intradermal injection for treating patients with advanced stage 
non-SCLC (113). It is worth mentioning that naturally occurring 
antibodies against TACAs have been detected in both, cancer 
patients and healthy donors (135, 136). In addition, TACA-
specific antibodies were screened in pooled sera of thousands of 
healthy donors. Notably, a structure–immunogenicity relation-
ship was observed (137). Thus, idiotypic vaccination could be an 
optimal way to activate immune response cascades involving the 
natural responses against these antigens. Recent results suggest 
the existence of antibodies against NeuGcGM3 with anti-tumor 
immune surveillance functions, reinforcing the importance of 
N-glycolylated gangliosides as anti-tumor targets (138, 139).
Other TACAs are GD2, ranking 12 out of 75 potential targets 
for cancer therapy by National Cancer Institute pilot program 
for the prioritization of the most important cancer antigens 
(140). Combination of anti-GD2 antibody (ch14.18) with IL-2 
and GM-CSF significantly improves survival for high-risk neuro-
blastoma patients (141, 142). The aforementioned study reflects 
the need to combine cancer immunotherapeutic treatments with 
other interventions. In this sense, safe transfer of CAR-based 
immunotherapy into clinical practice represents a potential 
alternative to conventional treatment options for cancer patients. 
Similar to GD3, CAR technology associated with GD2 has 
already shown significant anti-tumor activity in neuroblastoma 
patients (143, 144).
As mentioned in the previous section, tumor cells shed 
gangliosides and populate their microenvironment with these 
and other biologically active GSLs. Recently, strong evidences 
indicate that gangliosides synthesized and released by tumor 
cells have critical proangiogenic activity in  vivo, which is 
associated with enhanced tumor growth (145). These findings 
indicate that inhibition of human tumor ganglioside syn-
thesis could be a novel therapeutic target for human cancer. 
At this respect, N-butyldeoxynojirimycin, an imino-sugar 
TABLe 1 | Current and promising immunotherapeutic strategies involving tumor-associated gangliosides.
Ganglioside Type of 
treatment
Description Type of 
acquired 
immunity
Phase of 
clinical 
research
Type of human 
tumor
Reference
N-glycolyl-GM3 Anti-idiotype Ab 
(racotumomab)
Murine gamma-type anti-idiotype monoclonal antibody 
that specifically induces an antibody response to 
Neu5Gc-containing gangliosides, sulfatides, and other 
antigens expressed in tumors
Active Phase III trial Non-small-cell 
lung cancer
(102, 113, 114)
GD2 A chimeric 
Hu-murine 
antibody
Anti-GD2 Ab Ch14.18 + GM-CSF + IL-2 + isotretinoin Passive Phase I trial High-risk 
neuroblastoma
(115)
Anti-GD2 Ab (hu14.18K322A). Humanized anti-GD2 
Ab with a single point mutation (K322A) that reduces 
complement-dependent lysis
Phase I trial Refractory 
or recurrent 
neuroblastoma
(116)
Immunocitokine 
chimeric hu14.18 
Ab-IL2
Hu14.18-IL2 fusion protein consists of interleukin-2 
molecularly linked to a humanized monoclonal antibody 
that recognizes the GD2
Phase II trial Relapsed/
refractory 
neuroblastoma
(117)
metastatic 
melanoma
(118, 119)
CAR Natural killer-92 cells stably express a GD2-specific 
CAR, which carries a cell-binding domain derived from 
antibody ch14.18
Preclinical – (120)
Cell line: Hu neuroblastoma
Anti-idiotype Ab 
(gangliomab)
Immunization of Balb/c mice with 14G2a (murine 
monoclonal antibody to GD2), and splenocytes were 
harvested to generate hybridoma cells. Clones were 
screened for mouse antibody binding to hu14.18
Active Preclinical – (121)
Cell line: Hu neuroblastoma
Inhibitor Triptolide, a small molecule inhibitor, inhibits ST8-SiaI 
expression, GD2 biosynthesis, and cancer stem cells-
associated properties
– Preclinical – (122–124)
Cell line: Hu breast cancer/human tissue
GD3 Targeted delivery 
of cytotoxic 
agents
Secondary antibody coupled to Zap bounded to the 
mouse antibody to GD3 R24
– Preclinical – (109)
Cell line: Hu and mouse melanoma
Targeted delivery 
of cytotoxic 
agents
Secondary antibody coupled to Zap bounded to NG2 
and a GD3A9-O-acetyl GD3 antibodies
– (110)
Cell line: Hu glioblastoma multiforme
CAR Anti-GD3 tandem chimeric sFv-CD28/T-cell receptor 
zeta designer T cells. Second generation
Passive (90)
Cell line: human melanoma. Model animal: BALB/c 
nude mice
GM2 Synthetic 
carbohydrate-
based vaccines
Unimolecular pentavalent construct KLH conjugate 
(UPC-KLH, 2). Five prostate and breast cancer-
associated carbohydrate antigens, globo-H, GM2, STn, 
TF, and Tn conjugated to the carrier protein KLH
Active Preclinical – (125)
Model animal: mice (C57BL/6J)
Ab, antibody; NG2, neuron-glia 2 (a transmembrane chondroitin sulfate proteoglycan); CAR, chimeric antigen receptors; Hu, human; KLH, keyhole limpet hemocyanin; Tn antigen, 
Thomsen-nouvelle antigen (GalNAcα1-O-Ser/Thr); STn, sialyl-Tn; TF, Thomsen–Friedenreich antigen; Zap, saporin.
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administered orally to inhibit GlcCer synthase, delayed tumor 
development of MEB4 murine cells (146). This could be further 
explored in human cancer as a therapeutic approach, aiming 
at intervene on GSL metabolism of tumor cells and modulate 
GSLs shedding, thus lessening the immunomodulatory effects 
of GSLs (39).
Glycoengineering is another promising therapeutic approach 
for cancer (147). Essentially, a spectrum of scientific disciplines, 
such as carbohydrate chemistry, chemical biology, and glycobiol-
ogy, converge for creating improved or novel glycan products to 
control human health and disease (147). For instance, the first 
globo-H vaccine for clinical use was developed in 2001 (148). 
The cell-surface GSL globo-H is a member of a family of tumor-
associated antigens highly expressed on several types of cancers. 
Then, an optimized vaccine against the globo-H containing five 
prostate and breast cancer-associated carbohydrate antigens 
including GM2 was reported (125). More recently, a globo-H 
vaccine with different carriers and adjuvants was developed to 
improve the immunogenicity and safety profile (149). Over the 
last few years, some studies demonstrated an efficient metabolic 
glycoengineering of GM3 on melanoma cells with monoclonal 
antibody-mediated selective killing of glycoengineered cancer 
cells. Basically, cells were metabolically labeled both in vivo and 
in vitro with N-phenylacetyl-d-mannosamine (ManNPhAc) and 
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then selectively targeted and killed with a monoclonal antibody 
(2H3) recognizing both GM3NPhAc and ManNPhAc (150, 151).
COnCLUDinG ReMARKS
Cells becoming cancerous develop profound metabolic changes 
that influence plasma membrane composition. The expression/
overexpression of TACAs antigens such as gangliosides on cancer 
cell surface are involved in tumor evasion from the immune 
response. However, cancer therapy can exploit this undesirable 
expression as targets. Table 1 summarizes some of the current and 
promising cancer treatments aiming at gangliosides. Monoclonal 
antibodies clearly represent one of the most important strategies 
employed (152). Recent studies demonstrated how the levels of 
antibody-mediated inverse hormesis could differentially influ-
ence tumor growth (153). These findings may have important 
implications for cancer immunotherapy with antibodies, 
including those against glycolipids. Remarkable glycoengineer-
ing advances for the development of new and better anticancer 
antibodies, along with the design of novel and specific inhibitors 
of glycolipid synthesis or the precise delivery of cytotoxic agents, 
are renewing the applicability of gangliosides as targets for cancer 
therapy.
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